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Executive Summary  
 
ACMD Recommendation: 
The ACMD provisionally recommends that GBL and 1,4-BD are brought under 
control of the Misuse of Drugs Act 1971 and licensing arrangements are made 
for their legitimate industrial use.  
 
The ACMD considers that the harms and misuse of GBL and 1,4-BD are 
commensurate with Class C of the Misuse of Drugs Act 1971; classified in 
Schedule 1 of the Misuse of Drugs Regulations (having no recognised medicinal 
use).  
 
However, the ACMD is conscious of the potential impact of control upon the 
legitimate use of GBL and 1,4-BD and therefore also recommends that the 
Government consults specifically on this aspect, and that the Council has an 
opportunity to reconsider its conclusions following the outcome of the 
consultation. 
 
Summary 
Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are precursor 
chemicals that are rapidly converted (half-life approximately 1min) to the 
intoxicant gamma-hydroxybutyrate (GHB) when ingested into the human body.  
GHB occurs naturally in small amounts in the brain, and is recognised by specific 
receptors. It may be an inhibitory neuromodulator, involved among other things in 
the control of glucose metabolism, oxygen consumption and temperature 
regulation.  
 
The intoxicant dose for each chemical is approximately 1ml, and intoxication 
includes euphoria and loss of inhibitions; higher doses may lead to sedation and 
sleep.  There have been reports of emergency room admissions of patients 
overdosing on GBL or GHB, with coma, bradycardia and hypothermia. 11 GHB-
related deaths were reported in the EU in the period 1995-2000.  There is little 
evidence for widespread misuse of GBL or 1,4-BD, but as they are rapidly 
converted to GHB it is difficult to distinguish the misuse of these chemicals with 
that of GHB as only the latter compound can be detected in body fluids. Since 
the repeated use of GHB is known to lead to a dependence syndrome, it is likely 
that chronic use of GBL or 1,4-BD would carry a similar risk of dependence. 
There is some evidence for an increasing use of GBL as a “club drug”, and it has 
allegedly been used in drug-facilitated sexual assaults, although GHB was only 
detected in 2 of 344 such cases examined by the Forensic Science Service 
recently. GBL and 1,4-BD are readily available, at a cost of less than 10p per 
intoxicant dose. 
 
The Advisory Council on the Misuse of Drugs (ACMD) recommended that GHB 
be regulated as a Class C drug under the Misuse of Drugs Act, 1971 and this has 
been the case since July 2003. GBL and 1,4-BD are not controlled, although as 
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drug precursors they are subject to the EU Voluntary Monitoring list by which 
imports and exports are monitored.  
 
Both GBL and 1,4-BD are used in large quantities by the chemical industry, as 
precursors for the synthesis of plastics and industrial solvents. The UK Chemical 
Business Association reported that 1000 tons of GBL and 5000 tons of 1,4-BD 
are used annually in Britain – almost all imported from manufacturers in 
Germany. The ACMD’s Technical Committee asked the Home Office for 
information regarding mitigating options for any negative impact control may 
have on the industrial use of GBL and 1,4-BD. The ACMD understands that a 
licensing framework could be implemented that would not be overly burdensome 
for industry.  
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1.  Introduction 
 
1.1 The Advisory Council on the Misuse of Drugs (ACMD) is established 
under the Misuse of Drugs Act (1971) and its terms of reference and 
current membership are shown in Annexes 1 and 2 (respectively).  In 
January 2006 the then Home Secretary requested the Council to consider 
the issue of Drug Facilitated Sexual Assault. As part of their consideration, 
the Council identified the need to undertake a more comprehensive 
assessment of gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD).  
 
1.2 GBL and 1,4-BD (also abbreviated at BDO, BD or 1,4-B) are prodrugs of 
gamma-hydroxybutyrate (GHB). This means that they are rapidly 
converted to GHB in vivo (i.e. when the substance is ingested). Other 
related compounds with similarities to GHB include gamma 
hydroxyvalerate (GHV) and gamma valerolactone (GVL). 
   
1.3 There has been concern that users of GHB may have switched to using 
GBL and 1,4-BD since GHB was controlled under the Misuse of Drugs Act 
1971, as a class C substance on 1st July 2003. The potential change in 
drug using patterns and concerns that GBL and 1,4-BD have recently 
been implicated in drug facilitated sexual assault have triggered this 
report. 
 
1.4 The ACMD had considered GHB on several occasions prior to reaching its 
provisional decision to advise on the control of the drug. The ACMD had 
previously advised that, given the nature of the relationship between GHB 
and GBL, consideration should be given to the position of GBL under the 
Misuse of Drugs Act 1971 as a ‘loop-hole’ would be created if different 
action were taken in respect of GHB and GBL. 
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2. Background 
 
2.1 GBL is a prodrug of GHB which is a naturally occurring compound found 
in humans. GHB was isolated in 1960 and developed as a sedative 
medication and an anaesthetic. It is also used as a treatment for 
narcolepsy (Xyrem®), a rare neurological condition that is characterised 
by excessive daytime sleepiness. 
 
2.2 Reports of GHB misuse was first highlighted in the 1990s among 
bodybuilders who used it for its purported growth hormone stimulating 
effects. It was also bought as a sleep aid and as a dietary supplement. 
Gradually, reports of adverse events involving the use of GHB came to 
light. 
 
2.3 Reports that GHB could produce euphoria without hangover effects 
helped promote GHB as a ‘club drug’. It was also purported to enhance 
the effects of alcohol and stimulants as well as enhancing libido. This type 
of promotion helped GHB to become a popular niche drug as part of the 
night-club scene. 
 
2.4 GHB was classified as a Schedule I substance in the USA in 2000, and as 
a class ‘C’ drug (listed in Schedule 4, Part I of the regulations) in the UK in 
2003. Since then there has been concern that users have switched to 
GHB prodrugs such as GBL and 1,4-BD. Evidence of the use of GBL and 
1,4-BD has only recently come to public attention. 
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3. Pharmacology and Harmful effects 
 
 Pharmacodynamics 
3.1 GBL and 1,4-BD are rapidly converted to GHB, therefore the 
pharmacology of GHB must be reviewed in order to understand the effects 
produced. Furthermore, as the consequences of GBL and 1,4-BD 
ingestion are the same as GHB, studies do not usually characterise the 
drug ingested. This is further hampered as GBL and 1,4-BD are rapidly 
converted and are not detectable in plasma and urine samples. Therefore, 
information about the drug ingested is entirely reliant on a users self-
report. 
 
3.2 GHB was initially synthesised in order to produce analogues of the 
inhibitory neurotransmitter GABA, which could cross the blood, brain 
barrier. GABA is the precursor for GHB in human brains and the enzyme 
responsible for this reaction is GABA aminotransferase (Gonzalez and 
Nutt, 2005). 
 
 
Structures of neurotransmitter GABA, GHB and prodrugs GBL 
and 1,4-BD. 
   GABA 
GHB 
  GBL 
1,4-BD 
 
 
3.3 GBL and 1,4-BD are converted into GHB as soon as they are absorbed 
and in this respect should be treated as pro-drugs (see diagram below). 
GBL is converted by serum lactonases (or nonenzymic hydrolysis) 
whereas 1,4-BD is converted by alcohol dehydrogenase and 
aldehydedehydrogenase (Gonzalez and Nutt, 2005). 
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3.4 For a review of the effects of GHB in the brain see Gonzalez and Nutt, 
(2005). GHB has an effect on specific GHB receptors where it binds in a 
reversible manner. The receptor is a G-protein linked receptor and is 
widely distributed throughout the brain. It appears that GHB is an inhibitory 
neuromodulator and is associated with a range of brain functions such as 
control of glucose metabolism, oxygen consumption and temperature 
regulation. 
 
3.5 It is also likely that GHB activates GABAB receptors directly at 
concentrations above physiological levels to produce inhibition by 
reducing Ca2+ and lowering intracellular levels of cyclic AMP (Carter et al, 
2004;Sakaba and Neher, 2003). GHB can activate GABAB receptors 
indirectly when it is converted to GABA. 
 
 
 
 
3.6 As with most drugs of abuse, GHB has an effect on the dopamine system. 
However its actions are not clear with low doses seemingly disinhibiting 
dopamine cells causing increase dopamine release and higher doses 
causing inhibition of dopamine cells and thus diminished dopamine 
release (Cruz et al, 2004). 
 
3.7 There is some evidence that GHB has an effect on serotonergic and 
opioid receptor systems. However, these effects are likely to be subtle due 
to the wide range of functions affected by GHB. 
  GBL 1,4-BD 
  GHB 
GABA 
Succinic semialdehyde 
Serum lactonases Alcohol dehydrogenase and 
aldehyde dehydrogenase 
Succinic semialdehyde dehydrogenase / reductase 
GABA transaminase 
Converted into 
succinate and 
broken down 
via the Krebs 
cycle 
Metabolic pathways for ingested GBL and 1,4-BD  
  9
 
 Pharmacokinetics 
3.8 GBL and 1,4-BD are rapidly converted to GHB on ingestion. The half-life 
of GBL is approximately 1 minute (Gonzalez and Nutt,  2005). GHB itself 
is rapidly absorbed within 30 minutes in a dose dependent manner, serum 
levels peak 35-45 minutes after oral ingestion (Palatini et al, 1993). GBL is 
thought to be more readily absorbed which may be responsible for users 
saying its effects are more rapid (Nicholson and Balster, 2001). 
 
3.9 Once GBL and 1,4-BD are absorbed and converted, GHB circulates freely 
as it is not bound to plasma proteins. Distribution then follows a two 
compartment model. Initial blood levels decline rapidly, approximately 1 
hour after ingestion, followed by a slower period of metabolism. Clinical 
effects of the drug last approximately 3-4 hours (Gonzalez and Nutt, 
2005). 
 
3.10 Elimination of GHB appears to be non-linear, the rate-determining step is 
the activity of succinic semialdedyhe reductase (Struys et al, 2006). 
Elimination half-life of GHB is approximately 20 minutes, repeated dosing 
does not appear to affect metabolism (Ferrara et al, 1992). GHB can be 
detected in urine samples up to 8-10 hours and in blood samples 4-5 
hours after ingestion of GBL or 1,4-BD.  
 
Intoxication 
3.11 Effects for which users take GBL and 1,4-BD for include euphoria and 
disinhibition. Even at low doses, most users will also experience 
somnolence and confusion. As the dose response curve is very steep, 
many regular users have experienced toxicity, which is associated with 
many symptoms including nystagmus, aggression, urinary incontinence 
and nausea (Galloway et al, 1997; Miotto et al, 2001). 
 
3.12 Users report that GBL and 1,4-BD produce the same effects to GHB. Rats 
trained to discriminate saline from GHB showed that GBL produced cross-
generalisation and 1,4-BD also fully substituted for both GHB and GBL 
(Baker et al, 2005). However, the same animals did not substitute for 
benzodiazepines, alcohol and ketamine. These findings suggest GBL and 
1,4-BD produce similar subjective effects and that these are different from 
other sedating drugs. 
 
3.13 There are several published case series’ of patients with GBL and GHB 
overdoses attending emergency departments. In a Swiss study 65 
episodes of intoxication with GBL and GHB are detailed in 48 individuals 
(Liechti et al, 2006). Seven of the patients attended multiple times, two of 
whom presented 6 times. In the majority of episodes (42 occasions, 65%) 
another drug or alcohol was reportedly taken. 
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3.14 Typical signs and symptoms at presentation were coma, bradycardia and 
hypothermia. On 22 occasions (34%) coma was the initial presentation 
and was present in at total of 34 episodes (52%). Seizure-like movements 
were noted in 5 patients (8%). Interestingly, concomitant alcohol use was 
significantly associated with increased agitation and aggressive behaviour, 
whereas concomitant stimulant use was significantly associated with a 
deeper, more prolonged coma, and longer recovery times.  Four patients 
were intubated and monitored in an intensive care unit. There was no 
significant difference between GBL and GHB toxicity and no fatalities were 
reported. 
 
3.15 A case-series of 104 GHB overdoses presenting to an emergency 
department in Barcelona, Spain is reported (Miro et al, 2002). In this 
series, simultaneous alcohol consumption was reported in 73% and 
additional illicit drugs reported in 86% of cases. However, fewer cases 
presented in the Spanish study with coma than in the Swiss series (16% 
compared with 34% of cases) and mechanical ventilation was required 
less frequently. 
 
3.16 An early case series reports on 88 patients presenting to an emergency 
department in San Francisco, USA between 1993 and 1996 (Chin et al, 
1998). There was less concomitant use of alcohol (39%) and other illicit 
drugs (39%) than in the previous two series. However, rates of coma were 
high (28%) as were rates of bradycardia (36%) and hypothermia (31%). 
Twenty-six patients (30%) vomited and 21 (24%) had acidosis as 
measured by arterial blood gas sampling. 
 
3.17 An Australian study surveying 76 GHB users found that half (53%) had 
experienced a ‘GHB overdose’ (Degenhardt et al, 2003). This was despite 
the fact that, although the sample had limited experience with GHB, they 
were experienced users of other drugs. Overdose was defined as 
becoming unrousably unconscious; furthermore 53% had experience 
vomiting after GHB use. Eight percent of the sample had experienced a 
seizure like episode. 
 
3.18 Wood and Dargan report on a case series of 158 GHB/GBL patient 
presentations to the Emergency Department (ED) at St Thomas’ Hospital, 
London in 2006 (Wood and Dargan, oral presentation to the GBL Working 
Group). Of 1119 patient presentations with poisoning, 158 (14.1%) were 
for GHB/GBL intoxication. This represented 38% of all poisonings with 
drugs of abuse. Most had ingested GHB (95%) with only a minority 
reporting GBL ingestion (5%). Of the 8 patient presentations with reported 
GBL poisoning 7 were as a result of recreational use and 1 was a 
deliberate self-poisoning. 
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3.19 A significant number in the above study (25, 15.8%) had a Glasgow Coma 
Scale of 3 (range = 3-18) at presentation, the lowest score indicating 
severe coma. The majority (60.7%) were discharged home from the ED 
within 4 hours. However one patient died after accidental ingestion of a 
large volume of GHB. Most of the patients had other co-intoxicants, the 
most common being alcohol (34%), followed by Ecstasy (32%), and 
Ketamine (22%). For a significant number (35%) GHB/GBL was the only 
reported intoxicant. 
 
3.20 In all of the above case series for those patients not requiring mechanical 
ventilation consciousness was typically regained within 5 hours of 
ingestion. No deaths were reported in all three published case series, 
although one death is reported from accidental overdose in the London 
series. Of concern is the high rate of concomitant drug and alcohol use. 
The higher rates reported in the Spanish study may be due to the 
availability of toxicological evidence as to concomitant drug and alcohol 
use which may have been under-reported by patients in the other two 
series. Worryingly, a high number of people overdose with GHB and this 
will only become a greater hazard if users switch to GBL and 1,4-BD with 
variation in strength and different absorption rates making the judgement 
of the correct dose problematic. 
 
 GHB related death 
3.21 The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) reported that GHB was associated with 11 deaths in the EU 
between 1995 and 2000 (Gonzalez and Nutt, 2005). All deaths were in the 
UK or Scandinavia. A more recent study from Sweden reports that there 
were 7 GHB-related deaths in 2004 (Knudsen et al, 2005). It was also 
noted that cases of GHB intoxication following GBL and 1,4-BD use have 
come to light. 
 
3.22 A survey of the General Register Offices, cases referred to the Regional 
Laboratory for Toxicology, Birmingham and the National Programme on 
Substance Abuse Deaths (np-SAD) at St George’s Hospital (London) was 
presented to the GBL Working group by John Corkery, Programme 
Manager np-SAD. Data from 1993 to 2005 were available, although there 
is likely to be some overlap with those reported on in the study above. 
 
3.23    The np-SAD database identified 47 cases where GHB/GBL was found at 
post-mortem and/or implicated in death. Most cases identified were men 
(72%) and the mean age was 29.5years. The drugs reported at post 
mortem included GBL in 4 cases (9%) in all other cases GHB was the 
drug recorded. The coroner’s verdict was most commonly accidental 
overdose/misadventure (43.9%) (Appendix 4). 
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3.24 Four GHB associated deaths in Sweden are reported in detail (Timby et 
al, 2000). In all cases the cause of death was reported as acute circulatory 
and respiratory failure and, with the exception of ethanol, all other drugs 
found were not considered to be clinically important. Urine concentration 
of GHB ranged from 260-620 mcg/g, urine levels were considered to be 
more reliable as GHB is a product of post-mortem decomposition. 
 
3.25 For the decade from 1990 to 2000 the US Drug Enforcement Agency 
reported 68 GHB-related deaths (Miotto et al, 2001). It was only possible 
to identify information from one such case, a young adult female who took 
GHB in combination with alcohol (Nicholson and Balster, 2001). Another 
case report identifies a 35 year old male fatality who reportedly took GHB 
with some wine at a party (Mazarr-Proo and Kerrigan, 2005). GHB 
concentrations in the urine were 1665 mg/L, however no alcohol or other 
drugs of abuse were detected. 
 
3.26 A retrospective search for GHB related deaths in Australasia over an 18 
month period from January 2000 is reported (Caldicott et al, 2004). Ten 
cases of GHB-associated deaths were identified, with eight considered to 
be directly attributable to GHB. Only two of the eight cases were positive 
for ethanol toxicity. 
 
3.27 In summary, it appears evident that GHB and related compounds cause 
profound unconsciousness and that the steep dose response curve places 
even experienced users at risk from death by intoxication. There is some 
evidence that concomitant alcohol use may be a risk factor, but it is clear 
that intoxication with GHB and related compounds can cause death in 
isolation. 
 
 Dependence 
3.28 Dependence on GHB is a recognised clinical syndrome with similarities to 
alcohol dependence. Daily use of GBL and 1,4-BD is likely to produce the 
same clinical syndrome although, as yet, there are no published reports of 
dependence to these substances. There are reports on the internet of 
users becoming dependent on GBL and 1,4-BD with a clinical syndrome 
identical to that of GHB dependence (for example see 
www.erowid.org/experiences). 
 
3.29 The GHB dependence syndrome is well characterised in a report that 
surveyed 42 regular GHB users in the US (Miotto et al, 2001). Twenty-one 
percent of this self-selected sample reported being physically dependent 
on GHB with three patients taking GHB two hourly to avoid withdrawal 
symptoms. The authors report that they treated one user as an inpatient 
who developed delirium similar to that which develops in alcohol 
dependence. Tolerance was also a feature in regular users. 
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3.30 The users surveyed in the study above complained of frequent adverse 
events; loss of consciousness was reported by 66% and overdose by 
28%. The survey participants emphasized the positive effects of GHB and 
showed limited concern about the adverse experiences. Interestingly, 
family members called the investigators with anecdotal complaints of 
increased aggression, irritability and memory problems in those who used 
GHB. 
 
3.31 In Summary, regular GBL use and 1,4-BD use will produce a dependence 
syndrome. This diagnosis is based on a characteristic set of symptoms 
including; strong desire for a drug; poor control of drug usage; neglect of 
drug independent activities, persistence in drug use despite evidence of 
the harms caused; tolerance to the drug and a withdrawal syndrome.  
 
 Other 
3.32 GBL is described as a mild skin irritant and a strong mucous membrane 
irritant in its technical data sheet (ABPI Compendium of data sheets and 
summaries of product characteristics). It can penetrate the epidermis and 
cause rash or eczema. However there is no current evidence of any harm 
caused to internal membranes. 
 
3.33 A person intoxicated with GBL or 1,4-BD would be at risk of accidents if 
handling heavy machinery. Driving is likely to be hazardous in a similar 
way to being intoxicated with alcohol, with poor co-ordination and 
disinhibition producing greater risk taking. 
 
3.34 Reports of increased aggression (Liechti et al, 2006; Miotto et al, 2001) 
especially with concomitant alcohol use, coupled with disinhibition could 
result in unprovoked violence to others. This has a bearing on the risks to 
society if GBL and 1,4-BD use were to become more widespread. 
 
3.35 GBL has the potential to be used as an agent in drug facilitated sexual 
assault (also known as ‘date-rape’). GHB has been implicated in sexual 
assaults in the UK, other parts of Europe, and the US (Sturman, 1999). 
There is, at present, no evidence that GBL has been used in such 
assaults although detection of the substance and knowledge of the agent 
used by the victim is likely to be limited (see section 4).  
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4. Misuse 
 
 User groups 
4.1 GBL and 1,4-BD abuse has only recently been recognised, although it has 
been previously recognised as a analogue of GHB. The history of abuse 
of these substances is related to the rise of GHB use. During the 1980s 
GHB was widely available in the US as a dietary supplement at health-
food stores. Body-builders began using it to enhance muscle building and 
fat reduction. Reports of GHB use recreationally in night-clubs came to 
light in the early 1990s. By the end of this decade it had gained popularity 
as a ‘club-drug’ due to its purported euphoriant effects and sexual 
disinhibition. GHB use is common among a certain subset of gay men 
involved in ‘circuit parties’, sex clubs and at nightclubs (Halkitis and 
Palamar, 2006). There are no published case-series reports of GBL and 
1,4-BD use in bodybuilders, as a club-drug, or in gay communities.  
 
4.2 A study looked at patients presenting to the Accident and Emergency 
Department at St Thomas’ Hospital, London in 2006 (Wood and Dargan, 
oral presentation to the GBL Working Group). The authors identified 
significant numbers of people presenting for treatment following GBL and 
GHB ingestion in Vauxhall’s gay clubs. The majority of those presenting 
were in the 20-34 year old age group and almost all were male (94%). The 
authors report that people travel to Vauxhall from all over the UK and even 
Europe specifically for the gay clubbing scene in this area. 
 
 Dose and route of use 
4.3 GBL and 1,4-BD are clear liquids. There are very few reports detailing the 
taste of these compounds but one internet user describes GBL as “a 
greasy feeling solvent with a characteristic unpleasant smell”. This user 
goes on to say that the taste is unpleasant, like stale water. Some users 
have posted messages on user sites describing complicated techniques to 
turn liquid GBL into a powder form so as to produce capsules and to avoid 
the unpleasant taste. There are no reports of use by routes other than oral 
ingestion. 
 
4.4 Users report that GBL has a faster onset of action than GHB. Recreational 
doses of GHB in a non-dependent user are usually above 2.5g 
(approximately 35mg/kg) and are often measured as one capful. There is 
very little consistency on recreational doses of GBL due to the variety of 
preparations available. A recreational dose of high purity GBL (99.9%) 
would be about 1ml. Users report that this would give a similar effect to 
2.5g of GHB. GBL and 1,4-BD are approximately equipotent. 
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 Source and price 
4.5 GBL can be bought easily from traders on the internet. It can be 
purchased in sizes from 125ml to 10litres. A 250ml bottle of 99.9% pure 
GBL can be bought for £20, which equates to approximately 8p for a 
recreational dose (1ml). 
 
4.6 Although less readily available than GBL, 1,4-BD can also be bought from 
internet traders. Direct sales from chemical distribution companies are not 
available. 
 
 Drug facilitated sexual assault 
4.7 Reports of drug facilitated sexual assault (also known as ‘date-rape’) using 
GHB started to appear on the internet and in traditional media sources in 
the 1990s. Several properties of GHB and related compounds make them 
dangerous potential agents of drug facilitated sexual assault, these are: 
the low volume of dose required to elicit an effect; its ability to cause 
drowsiness or even unconsciousness, disinhibition, amnesia, and its fast 
elimination from body fluids therefore making it difficult to identify in 
samples taken from victims. GBL and 1,4-BD have an unpleasant taste 
but due to the small volumes necessary for assault this may not be 
noticed if added to a strongly flavoured drink. Both GBL and 1,4-BD are 
fully miscible with water. 
 
4.8 A large toxicological study from the UK has reported on agents identified 
in 1014 cases of alleged drug facilitated sexual assault submitted to the 
Forensic Science Service over a two year period (Scott-Ham and Burton, 
2005). It was not possible to distinguish between cases of GHB, GBL and 
1,4-BD in the study and all were considered together. In only 2 cases 
could the presence of GHB or a related compound be confirmed out of 
344 cases where a common drug of abuse (cannabis, cocaine, ecstasy, 
amphetamine, heroin and ketamine) was detected (0.6%). However, this 
may be an under-estimate of actual cases as these substances are 
undetectable in blood samples taken more than 6-8 hours, and urine 
samples taken more than 12-18 hours, after ingestion.  
 
4.9 An earlier study from the US reports on the analysis of 1179 samples 
collected from victims of alleged drug facilitated sexual assault (Elsohly 
and Salamone, 1999). GHB or related compounds were found in 48 cases 
(4% of the total sample). The variation between this and the UK study may 
be due to different detection methods for assessing the presence of 
endogenous GHB in the body. 
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5. Seizures and Intelligence 
 
5.1 Her Majesties Revenue and Customs (HMRC) cannot seize importations 
of GBL and 1,4-BD as they are not currently controlled in the UK. 
However, under European Union (EU) regulations imports and exports of 
GBL and 1,4-BD are monitored by EU customs authorities under the EU 
voluntary monitoring list. 
 
5.2 HMRC have reported several instances of GBL being privately imported 
by individuals from legitimate suppliers and then being repackaged for 
export abroad (see HMRC report, Annex 2). GBL is ordered on internet 
sites from companies in the Netherlands, Israel and China. It has been 
imported in large amounts; in June 2006 a consignment of 1000kg was 
imported from China by sea container, purchased for £2,200 (see below). 
The chemicals are declared as various substances including video 
cleaner, wool cleaner, and magic stain remover. 
 
 
Five 200kg steel drums recently imported by a private individual from China 
(photo courtesy of Joe Onofrio, HMRC). 
 
5.3 It is estimated that one company exported 3405 litres of repackaged GBL 
from the UK to the USA and Canada between 2001-2004 in approximately 
800 separate parcels. Other importers have been thought to have 
packaged GBL for distribution within the UK and abroad.  
 
  17
5.4 The Forensic Science Service reported 2 seizures of GBL liquid totalling 
500ml in the first three months of 2006. In the same period 23 seizures of 
GHB, totalling 2.7kg of powder and 1640ml of liquid, were recorded.  
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6. Commercial use 
 
6.1 GBL and 1,4-BD have a wide variety of legitimate uses. Both chemicals 
are imported and used in large volumes by the manufacturing industry and 
distributed by the chemical distribution companies. Many of the companies 
that handle GBL and 1,4-BD in the UK are members of the Chemical 
Business Association (CBA). The CBA represents members’ interests in 
the UK and Europe and promotes industry standards. The CBA co-
ordinates ‘Responsible Care’, the industries voluntary code to safeguard 
health and safety within the industry, including diversion of potentially 
harmful chemicals. 
 
6.2 The CBA reports that 1,000 tons of GBL and 5,000 tons of 1,4-BD are 
imported to the UK per annum. The chemicals are manufactured in 
Germany and shipped to the UK in sealed containers. The chemicals are 
not supplied without ‘end-user’ certificates i.e. documents describing how 
the compounds will be used. The majority of the imported GBL and 1,4-BD 
is used by a few large companies. 
 
6.3 GBL can be used in consumptive industrial processes. This means that 
GBL will be consumed during manufacturing without being part of a new 
product. GBL is used in this way as a solvent in recrystallisation processes 
or as a solvent in the electronics industry. GBL is commonly used as a 
component in the manufacture of various cleaning agents and paints, 
where it remains as part of the finished product. 
 
6.4 Much of the 1,4-BD imported is used as a raw material in the production of 
plastics and rubber, for example as polyurethane elastomers (e.g. 
Spandex). However it is also used as a solvent or binding agent in the 
manufacture of other products, for example paints and coatings. 
 
6.5 Due to the large volumes of GBL and 1,4-BD handled by UK companies it 
would be impossible to rule out small scale diversion from legitimate 
supplies. However the voluntary code, to which all members of the CBA 
are signed up to includes measures to reduce the possibility of diversion. 
The code includes internal audit of supply and distribution, identification of 
suspicious orders and ‘declaration of use’ documentation for 1,4-BD and 
GBL that is sold on to other customers. 
 
6.6 In summary both GBL and 1,4-BD are widely used chemicals in UK 
industry. They have a reputation as being safe and environmentally 
friendly and there are currently no clear alternatives that industry could 
easily switch to if the use of these chemicals became logistically difficult 
due to increased legislation. It appears that much more readily available 
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sources of GBL and 1,4-BD are overseas based internet sites selling pure 
GBL and 1,4-BD directly to the small scale consumer. 
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7. GBL & 1,4-BD control in other countries 
 
 The USA 
7.1 In the US the Food and Drug Administration (FDA) banned over-the-
counter sales of GHB in 1990. Since 2000 GHB has been under strict 
control when it was classified as a Schedule I substance (equivalent to 
heroin and cocaine) by the National Institute of Drug Abuse (USA). GBL 
and 1,4-BD are not scheduled but GBL is classified as a list 1 chemical 
and a controlled substance analogue, while 1,4-BD is listed as a controlled 
substance analogue. 
 
7.2 A report from the US Substance Abuse and Mental Health Service 
Administration (SAMHS) found that the number of visits to Emergency 
Departments in which GHB and GBL were mentioned increased from 56 
in 1994 to 4,969 in 2000 (Office of Applied Studies, 2002). There is no 
available epidemiological data investigating the impact of the change of 
legal status of GHB and the effect on use of GBL and 1,4-BD in the US. 
 
 Europe 
7.3 GHB has a varied level of control across the European Union (EU) with 
some member states controlling it under misuse of drugs legislation 
whereas in others it is controlled by medicines acts. There is more 
widespread clinical use of GHB elsewhere in the EU where it is used for 
the treatment of Narcolepsy, as an anaesthetic agent, a hypnotic, and a 
treatment for alcohol dependence. 
 
7.4 In Switzerland use of GHB was prohibited in December 2001. Prior to 
1999, cases of GHB overdoses presenting to emergency departments 
were very rare, less than 5 cases a year (Liechti and Kupferschmidt, 
2004). Cases of GBL overdoses became apparent in 1999, and in 2002 
and 2003 reports of GBL intoxication began to replace GHB cases. This is 
the first evidence of a change to the legal status of GHB potentially 
impacting on the use of GBL. 
 
7.5 There are published reports of GHB use in Scandinavia (Drasbek et al, 
2006) and in Barcelona (Miro et al, 2002) where GHB intoxication 
represented 18% of all emergency department admissions by illicit drug 
consumption. However epidemiological data is not routinely collected and 
whether GBL or 1,4-BD was ingested is not reported. 
 
7.6 The EU recently considered adding GBL and 1,4-BD to the UN list of pre-
cursor chemicals, but this was rejected. It was agreed to place GBL and 
1,4-BD on the EU voluntary watch list so that customs authorities had 
better information about the distribution of these chemicals. 
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 Australasia 
7.7 GHB, but not GBL and 1,4-BD, is a scheduled drug under the misuse of 
drugs legislation in New Zealand and Australia. There are GHB associated 
deaths reported in both these countries (Caldicott et al, 2004). A survey of 
GHB users in Australia found that experience of unconsciousness (52%) 
and vomiting (53%) following use was high (Degenhardt et al, 2002). 
Although authorities are aware of the potential of GBL and 1,4-BD use, 
there were no reported episodes from Australasia (Degenhardt et al, 
2005). 
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8. Harm Reduction Strategies  
 
8.1 Dr David Woods and Dr Paul Dargan (Guys and St Thomas Hospital) 
reported on a pilot project to improve the referral of ‘poisoned’ clubbers 
(presentation to the GBL and 1.4 Butanediol Working Group: March 2007). 
Strategies were targeted at specific areas working with clubs in the 
Vauxhall area of London, the Metropolitan Police Service, the Emergency 
Department (ED) at St Thomas’ Hospital, and the Clinical Toxicology 
Service at the Guy’s and St Thomas’ Poisons Unit. 
 
8.2 In the clubs, efforts have been made to improve awareness of door staff in 
recognising GHB/GBL disguised in containers purporting to be legitimate 
liquids. Training of door staff was undertaken and supervised by the 
Metropolitan Police. A training programme was instigated for members of 
club staff to act as club ‘medics’. Staff would then be better able to 
recognise the signs of GHB/GBL intoxication and facilitate appropriate 
referral to the Emergency Department. Guidelines have also been 
developed and distributed in clubs and bars. 
 
8.3 Dr David Woods and Dr Paul Dargan reported to the GBL and 1.4 
Butanediol Working Group (March 2007) that they have audited and 
revised their guidelines and implemented subsequent training sessions. 
However it is too early in the scheme for evidence to be gathered on 
whether these strategies have had an impact on the number and severity 
of cases seen at the ED at St Thomas’ Hospital. 
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9. Conclusions 
 
9.1 GBL and 1,4-BD are rapidly converted to GHB once ingested. It is 
established that GHB is associated with coma and death in overdose and, 
because of its level of harms, has already been considered and classified 
under the Misuse of Drugs Act 1971. Therefore there is an a priori case for 
considering control of GBL and 1,4-BD. 
 
9.2 GBL and 1,4-BD are widely used by the chemical industry in the UK. 
Regulation is therefore more complex for these substances as it has the 
potential to have a detrimental impact upon these industries. 
 
9.3 There is little evidence that GBL and 1,4-BD are being used recreationally 
in the UK. However seizure evidence suggests there is a market for these 
substances.  
 
9.4 Voluntary control within the chemical industry is seemingly effective. 
However, supplies of GBL and 1,4-BD are readily available on the 
internet. There is some evidence of end-product use. 
 
9.5 There is potential for GBL and 1,4-BD to be used as weapons in drug 
facilitated sexual assault. GHB has been implicated in sexual assault in 
the UK, other parts of Europe, and the US (Sturman, 1999). The law 
enforcement agencies have reported 233 seizures of GHB between 2001 
and 2006.    
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10. Options 
 
10.1 Options considered by GBL Working Group and presented to the 
Technical Committee: 
 
Option 1 
Classify GBL and 1,4-BD under the Misuse of Drugs Act 1971. This would bring 
these two substances into line with GHB thereby closing the loop-hole that 
currently exists. However, this step may have a detrimental effect on the 
chemical industry in the UK and may be perceived to be out of proportion to the 
level of reported use currently. Limitations to classification could be considered to 
reduce the impact on the chemical industry. 
 
Option 2 
Call for tightening of the existing voluntary codes within the chemical industry. 
However, it is likely that this would have little impact on the recreational misuse 
of GBL and 1,4-BD as it is readily available from internet suppliers outside the 
remit of the UK chemical industry. The option of adding unpleasant chemicals, for 
example the unpleasant tasting Bitrex, to GBL and 1,4-BD imported to the UK 
could also be considered. However, this could also be bypassed by internet 
sources outside the UK or EU. 
 
Option 3 
Lobby for the inclusion of GBL and 1,4-BD in the EU Precursor Chemical 
Legislation. The aim of this option is to affect the import and export of GBL and 
1,4-BD, although may be bypassed by sources outside the EU.  However, we 
have subsequently been advised that this option is not viable.  The EU Precursor 
Chemical Legislation is designed to monitor the movement and supply of 
chemicals which can be used to manufacture drugs of misuse, rather than to 
restrict the supply of industrial products which in themselves can be misused.  As 
such, the inclusion of GBL and 1,4-BD into European Precursor legislation does 
not reflect the purpose of the legislation and would not be operationally viable, or 
constitutionally proper. 
 
Option 4 
Include GBL and 1,4-BD into a Home Office licensing system.  However, the 
working group was concerned that it might place an unnecessary and 
disproportionate burden on an industry which is already effectively policing itself.  
There is very little diversion from legitimate industrial uses, and as such a 
licensing system seems excessive for these companies.  Furthermore, it may still 
be bypassed by internet sources, where the true problem stems from. 
 
Option 5 
Watch and wait. As there is only a small body of published evidence of the 
recreational misuse of GBL and 1,4-BD it may be unwarranted to introduce 
legislative change at this stage. This option would encourage greater reporting 
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and evidence gathering to enable a more informed decision to be reached in the 
future. 
 
 
10.2  Having considered the above options the Working Group concluded that 
there are essentially only two available options: Option 1 to bring GBL and 
1,4-BD under control of the Misuse of Drugs Act, 1971, with or without a 
combination of Option 4 to include GBL and 1,4-BD in a licensing system; 
or Option 5 watch and wait.  
 
10.3   After consideration of the evidence presented in this report and the options 
outlined above, the ACMD recommends that GBL and 1,4-BD are brought 
under control of the Misuse of Drugs Act 1971 and licensing arrangements 
are made for their legitimate industrial use. The harms and misuse of GBL 
and 1,4-BD are considered commensurate with Class C of the Misuse of 
Drugs Act 1971; classified in Schedule 1 of the Misuse of Drugs 
Regulations (having no recognised medicinal use).  
However, the ACMD is mindful of the potential impact of control upon the 
legitimate use of GBL and 1,4-BD and therefore also recommends that the 
Government consults specifically on this aspect, and that the ACMD 
comments further following the outcome of the consultation before 
finalising its recommendation. 
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Annex 1. Terms of Reference of the Advisory Council on the Misuse of 
Drugs 
 
“ It shall be the duty of the Advisory Council to keep under review the situation in 
the United Kingdom with respect to drugs which are being or appear to them 
likely to be misused and of which the misuse is having or appears to them 
capable of having harmful effects sufficient to constitute a social problem, and to 
give to any one or more of the Ministers, where either Council consider it 
expedient to do so or they are consulted by the Minister or Ministers in question, 
advice on measures (whether or not involving alteration of the law) which in the 
opinion of the Council ought to be taken for preventing the misuse of such drugs 
or dealing with social problems connected with their misuse, and in particular on 
measures which in the opinion of the Council, ought to be taken:  
  
a)         for restricting the availability of such drugs or supervising the 
arrangements for their supply; 
 
b)         for enabling persons affected by the misuse of such drugs to obtain 
proper advice, and for securing the provision of proper facilities and services for 
the treatment, rehabilitation and after-care of such persons; 
  
c)         for promoting co-operation between the various professional and 
community services which in the opinion of the Council have a part to play in 
dealing with social problems connected with the misuse of drugs; 
  
d)         for educating the public (and in particular the young) in the dangers of 
misusing such drugs and for giving publicity to those dangers; and  
  
e)         for promoting research into, or otherwise obtaining information about, any 
matter which in the opinion of the Council is of relevance for the purpose of 
preventing the misuse of such drugs or dealing with any social problem 
connected with their misuse”.  
  
A further duty is placed on the Council by the Act to consider any matter relating 
to drug dependence or the misuse of drugs which may be referred to them by 
any one of the Ministers concerned, and in particular to consider and advise the 
Home Secretary on any communication which he refers to the Council which 
relates to the control of a dangerous or otherwise harmful drug and which is 
made to Her Majesty’s Government by any organisation or authority established 
by treaty, convention or other agreement or arrangement to which Her Majesty’s 
Government is a party. 
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Annex 2. Membership of the Advisory Council on the Misuse of Drugs 
(November 2007) 
 
 
Professor Sir Michael Rawlins  Professor of Clinical Pharmacology, University 
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University Medical School, Harplands Hospital 
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Council Education Department 
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Annex 3. HM Revenue and Customs  
 
In bringing the report into the public domain, the ACMD has had to make a 
number of redactions to this Annex which have been made with careful 
consideration of the details of the specific information and sensitive data; 
in line with Home Office guidance. 
 
GAMMA –BUTYROLACTONE  (GBL) & 1,4 BUTANEDIOL 
(1,4-BD). 
 
1. GBL: THE PRODUCT 
Gamma-Butyrolactone (GBL). 
CAS No 96-48-0 
Harmonised Tariff Code 2932.29. 5010 
Molecular Formulae C4 H6 O2. 
Boiling Point 204 C (335 F). 
Density 1.12. 
 
• GBL is the only known precursor to gamma- hydroxy butyrate (GHB) 
which became a Schedule 1 drug in the USA on March 2000. (In 27 
States). 
 
• GBL is manufactured in the USA, Spain, Italy, Belgium, France and 
Switzerland. It is also manufactured in Japan, India and China. 
 
 
HMRC Seizures. 
• HMRC cannot seize importations of GBL/1,4-BD as they are not controlled 
in the UK. 
 
• As long as the imports are properly declared and all UK import Duties and 
VAT are paid no Customs offence’s have been committed. 
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Annex 4: GHB/GBL deaths in the UK - some initial findings  
 
INTERNATIONAL CENTRE FOR DRUG POLICY NATIONAL PROGRAMME 
ON SUBSTANCE ABUSE DEATHS 
 
         
Introduction 
 
Presented are the results from a survey of the General Register Offices, cases 
referred to Dr Simon Elliott, The Regional Laboratory for Toxicology Dudley 
Road, Winson Green Birmingham, and the National Programme on Substance 
Abuse Deaths at St George's, University of London.  Thanks to all concerned for 
supplying data. 
 
The information given in this paper is being provided with the approval of 
Professor Hamid Ghodse, Director of the International Centre for Drug Policy, to 
enable as complete a picture from currently available information to be presented 
to the ACMD GBL/1,4BD Working Group for their consideration.  
 
General Register Offices – GHB mentions on death certificate 
 
Northern Ireland (to date) - 0 
Scotland (1994 to 2005) - 5 
England & Wales - ONS data (1993-2005 registrations) – 24 
Combining these data gives the following frequencies by year 
 
  England & Wales Scotland 
1996   1   
1999   3   1 
2000   3 
2001   1   2 
2002   5   2 
2003   6 
2004   1    
2005   4 
 
 
 
 
 
 
 
 
 
 
  35
National Programme on Substance Abuse Deaths (np-SAD), St George's 
University of London 
 
At the time of writing, the np-SAD database has details of 47 named individuals 
where GHB/GBL was either found at post mortem and/or implicated in death. In 
addition, we are aware of a number of further cases where these substances 
have been found at post mortem and for whom we are currently seeking further 
information.  The overall total of 47 cases includes the 5 Scottish cases referred 
to above - 3 of which are on the database.  
 
There may be other cases yet to be notified to np-SAD but we are canvassing 
toxicologists to see if there are any other cases out there. Dr Elliott is assisting in 
this research as he often has cases from other areas referred to him for analysis; 
his PhD thesis was concerned with the application of special techniques to 
determine the presence of GHB/GBL.  
 
Furthermore, some deaths involving GHB/GBL may not be identified as such 
because these substances have not been specifically tested for. 
 
It is possible that closer examination of 2 of the cases may result in them being 
excluded as GHB/GBL cases due to he low levels found at post-mortem. Since 
GHB naturally occurs in the human body, it can sometimes be difficult to 
determine if it was produced by the body or ingested e.g. if there is no 
circumstantial evidence available. 
 
In all of these instances it should be noted that the fact that a drug is recorded as 
being present post mortem or indeed recorded on the death certificate does not 
necessarily imply that it contributed to the death. 
 
The following brief analyses are based on these 47 cases. 
Results 
Year of death 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 1995 1 2.1 2.1 2.1
  1997 1 2.1 2.1 4.3
  1998 2 4.3 4.3 8.5
  1999 3 6.4 6.4 14.9
  2000 3 6.4 6.4 21.3
  2001 7 14.9 14.9 36.2
  2002 7 14.9 14.9 51.1
  2003 3 6.4 6.4 57.4
  2004 3 6.4 6.4 63.8
  2005 6 12.8 12.8 76.6
  2006 11 23.4 23.4 100.0
  Total 47 100.0 100.0  
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Age-group at death 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 15-24 14 29.8 30.4 30.4
  25-34 23 48.9 50.0 80.4
  35-44 8 17.0 17.4 97.8
  45-54 1 2.1 2.2 100.0
  Total 46 97.9 100.0  
Missing System 1 2.1   
Total 47 100.0   
 
 
Age at death  
Valid 46N 
Missing 1
Mean 29.5621
Median 28.9979
Range 27.06
Minimum 19.95
Maximum 47.01
 
Gender 
  Frequency Percent
Valid 
Percent 
Cumulative 
Percent 
Valid male 34 72.3 72.3 72.3
  female 13 27.7 27.7 100.0
  Total 47 100.0 100.0  
 
Ethnicity 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid NOT KNOWN 3 6.4 7.0 7.0 
  WHITE 37 78.7 86.0 93.0 
  BLACK 
CARRIBEAN 1 2.1 2.3 95.3 
  BANGLADESHI 1 2.1 2.3 97.7 
  OTHER 1 2.1 2.3 100.0 
  Total 43 91.5 100.0   
Missing System 4 8.5    
Total 47 100.0    
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Occupation Status condensed 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid not known 2 4.3 4.5 4.5 
  unemployed 5 10.6 11.4 15.9 
  employed 29 61.7 65.9 81.8 
  childcare/houseperso
n 2 4.3 4.5 86.4 
  student/pupil 4 8.5 9.1 95.5 
  other 2 4.3 4.5 100.0 
  Total 44 93.6 100.0   
Missing System 3 6.4    
Total 47 100.0    
 
Living Arrangements condensed 
  Frequency Percent
Valid 
Percent 
Cumulative 
Percent 
Valid not known 1 2.1 2.3 2.3 
  with others 25 53.2 56.8 59.1 
  alone 18 38.3 40.9 100.0 
  Total 44 93.6 100.0   
Missing System 3 6.4    
Total 47 100.0    
 
 
Category of place of death 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Defined residential 
address 30 63.8 66.7 66.7 
  Hospital/infirmary 11 23.4 24.4 91.1 
  other 4 8.5 8.9 100.0 
  Total 45 95.7 100.0   
Missing System 2 4.3    
Total 47 100.0    
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Accident Site 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid not known 1 2.1 2.5 2.5 
  home 21 44.7 52.5 55.0 
  street or highway 2 4.3 5.0 60.0 
  place of 
recreation/sport 1 2.1 2.5 62.5 
  other specified place 15 31.9 37.5 100.0 
  Total 40 85.1 100.0  
Missing System 7 14.9   
Total 47 100.0   
 
 
 
Drug Addict status 
  Frequency Percent
Valid 
Percent 
Cumulative 
Percent 
Valid NOT 
KNOWN 6 12.8 13.0 13.0 
  YES 25 53.2 54.3 67.4 
  NO 15 31.9 32.6 100.0 
  Total 46 97.9 100.0   
Missing System 1 2.1    
Total 47 100.0    
 
Coroner's Verdict 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
dependence on drugs 1 2.1 2.3 2.3
non-dependent abuse of 
drugs 7 14.9 16.3 18.6
accidental / 
misadventure 20 42.6 46.5 65.1
open 
verdicts/unascertained 6 12.8 14.0 79.1
all other verdicts 7 14.9 16.3 95.3
abuse of drugs 2 4.3 4.7 100.0
Valid 
Total 43 91.5 100.0  
Missing System 4 8.5    
Total 47 100.0    
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Part of UK where death occurred 
Country/Region Frequency 
Northern Ireland 0 
Scotland 7 
Wales 5 
England 35 
GOR area  
Greater London 10 (including 6 in Inner South) 
Yorkshire 7 
Greater Manchester 4 
North West 4 
Midlands 4 
North East 2 
Eastern  1 
East Anglia 1 
South West 1 
Not known 1 
 
 
Number of drugs at PM 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 1 6 12.8 13.0 13.0
  2 6 12.8 13.0 26.1
  3 13 27.7 28.3 54.3
  4 9 19.1 19.6 73.9
  5 6 12.8 13.0 87.0
  6 3 6.4 6.5 93.5
  7 2 4.3 4.3 97.8
  10 1 2.1 2.2 100.0
  Total 46 97.9 100.0  
Missing System 1 2.1   
Total 47 100.0   
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Combinations of PM drugs 
Post mortem substances Frequency 
Alcohol 1 
Alcohol, amphetamines, MDMA, MDA (no GHB pm) 1 
GBL 1 
GHB 4 
Alcohol & GHB 4 
Alcohol, GHB & hormones 1 
Alcohol, GBL & cocaine 1 
Alcohol, GHB & cocaine 3 
Alcohol, GHB & chlordiazepoxide 1 
Alcohol, GHB, MDMA 1 
Alcohol, GHB, MDMA, MDA, cannabis 2 
Alcohol, GBL, MDMA, cocaine & temazepam 1 
Alcohol, GHB, MDMA, MDA, cocaine, diazepam & dextropropoxyphene 1 
Alcohol, GHB, MDMA, MDA, cocaine, diazepam, diltiazem 1 
Alcohol, GHB, methamphetamine, cocaine & benzodiazepines 1 
Alcohol, GHB, MDMA, MDA, cocaine & olanzapine 1 
Alcohol, GHB, amphetamine, diazepam, heroin, phenobarbitone 1 
Alcohol, GHB, ecstasy, amphetamines, ketamine & cannabis  1 
Alcohol, GHB & diazepam 1 
Alcohol, GHB/GBL & diazepam 1 
Alcohol, GHB, diazepam & dextropropoxyphene 2 
Alcohol, GHB, diazepam & cocaine 1 
Alcohol, GHB, codeine, paracetamol, zopliclone 1 
Amphetamines & GHB 1 
Amphetamines, GHB & alcohol 1 
GHB, MDMA & MDA 1 
GHB (GBL), MDMA, MDA, amphetamine, methamphetamine, temazepam  1 
GHB, ecstasy & cocaine 1 
GHB, MDMA, MDA, cocaine & ketamine 1 
GHB, ecstasy, cannabis & lithium 1 
GHB, cocaine, diazepam, atropine & lignocaine 1 
GHB, diazepam & cannabis 1 
GHB, diazepam, cannabis, morphine, codeine, temazepam, oxazepam 1 
GHB, diazepam & codeine 1 
GHB, desmethyldiazepam, morphine, chlordiazepoxide 1 
GHB, benzodiazepines, codrydramol, paracetamol, diclofenac 1 
NA 1 
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Levels of GHB/GBL (inc. Ante-Mortem) 
Case 
no. 
GHB GBL Alcohol Stimulants 
present 
Other 
drugs (inc. 
stimulants) 
present 
 blood urine blood urine blood urine   
1 340 mg/L    202    
2 1400mg/L      Y Y 
3 34.5mg/dL    116 136   
4 120mg/L 680mg/L   131 198 Y Y 
5 420mg/L      Y Y 
6     Y    
7 340ug/ml    Y  Y Y 
8 305ug/ml      Y Y 
9 120ug/ml 1mg/ml      Y 
10 356mg/L    47    
11 110mg/L       Y 
12 340ug/ml 1200ug/ml   265 370  Y 
13 267mg/L 90mg/l   106 146   
14   189ug/ml 1mg/ml 200 261 Y Y 
15 360mg/L 796mg/L   196 297  Y 
16 120mg/L    77 132 Y Y 
17 260mg/L      Y  
18 18ug/ml    240   Y 
19 139mg/L    57  Y  
20 5ug/ml       Y 
21   300ug/ml  195 264 Y  
22 129mg/L    29 18 Y Y 
23 0.17mg/ml 2.4mg/ml   79    
24 270mg/L 824mg/L   47  Y Y 
25 159mg/L 1464mg/L       
26 200mg/L      Y Y 
27 1575mg/L 1980mg/L       
28 220mg/L 2708mg/L   111 133 Y Y 
29 79.8ug/ml    217  Y  
30 >10mg/L       Y 
31 30ug/ml    97 127  Y 
32 45mg/L       Y 
33 64mg/L 1150mg/L     Y Y 
34 100mg/L    97  Y  
35 430ug/ml 
AM 
 6500ug/ml 
(PM) 
     
36   800mg/L    Y Y 
37 96mg/dL    154   Y 
38  3ug/ml   1  Y Y 
39 14mg/L    156  Y  
40 42mg/L        
41 NA        
42 22mg/l            15        10 Y Y 
43 NA      Y Y 
44 NA        
45 106mg/L 110mg/L + + 180 228  Y 
46 403mg/L 0mg/L       
47 NA    190 264 Y Y 
 
 
  42
Combinations of implicated drugs 
Substances implicated Frequency 
Alcohol 1 
MDMA 2 
Methadone 1 
GBL 1 
GHB 6 
Alcohol & cocaine 1 
Alcohol & GHB 6 
Alcohol, GBL & cocaine 1 
Alcohol, GHB & cocaine 2 
Alcohol, GHB, MDMA 2 
Alcohol, GBL, ecstasy, cocaine & temazepam 1 
GHB, amphetamines &  ketamine  1 
GHB, ecstasy & ketamine 1 
Alcohol, GHB & diazepam 1 
Alcohol, GHB, diazepam & dextropropoxyphene 2 
Alcohol, GHB, diazepam & cocaine 1 
Amphetamines & GHB 1 
Amphetamines & GHB/GBL 1 
GHB & cocaine 2 
GHB, MDMA  2 
GHB, ecstasy & cocaine 1 
GHB, ecstasy, cannabis & lithium 1 
GHB & diazepam 1 
GHB, diazepam & codeine 1 
GHB, benzodiazepines& paracetamol 1 
None 2 
NA 4 
  
Circumstances of death/events leading up to death 
Circumstances Frequency 
Following gym session, heavy meal & alcohol, took GHB to assist sleep & 
body building 
1 
Consumed after drinking to help sleep 1 
Preceding recreational use of other substances  2 
Experimentation following alcohol consumption 5 
Recreational use following alcohol consumption 2 
Recreational use with alcohol consumption 3 
Recreational use with alcohol and stimulants 4 
Recreational use after alcohol and other drugs 5 
Following use of GHB and other recreational drugs 1 
Following use of GHB and heroin 1 
Following use of GHB and cocaine (injecting & snorting)  
Consumed after socialising 2 
Found collapsed 3 
Collapsed at club 1 
Found dead at home 2 
Administered by third party after use of recreational drugs 2 
Found dead in car after taking analgesics & benzodiazepines 1 
Rode bicycle into path of bus 1 
Mistaken for water, anaphalactic shock 1 
Found dead following fire 1 
Drowned after taking drugs and drinking                                                            1 
Not known/not available 6 
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Underlying cause(s) of death 
Cause Frequency 
Ingestion of GHB & alcohol 1 
Ingestion of GHB, alcohol, MDMA 1 
Fatal medical complications following combination of drugs (GHB, codeine, 
diazepam) 
1 
Effects of multiple drug ingestion (GHB, dextropropoxyphene, alcohol, 
diazepam) 
1 
Effects of GBL, alcohol, cocaine & ecstasy 1 
GHB intoxication 4 
GHB & amphetamine intoxication 1 
GHB, ketamine, ecstasy intoxication 1 
Alcohol toxicity 1 
Alcohol & cocaine poisoning 1 
MDMA poisoning 1 
Methadone toxicity 1 
GHB toxicity 4 
GHB & alcohol toxicity 5 
GHB, alcohol & cocaine toxicity 2 
GBL alcohol & cocaine toxicity 1 
GHB, alcohol & diazepam toxicity 1 
GHB, alcohol, diazepam & dextropropoxyphene poisoning 1 
GHB, alcohol & MDMA poisoning 1 
GHB & amphetamine toxicity 1 
GHB, amphetamine & ketamine toxicity 1 
GHB & cocaine toxicity 2 
GHB, cocaine & ecstasy toxicity 1 
GHB & diazepam toxicity 1 
GHB, ecstasy & cannabis overdose 1 
GHB & MDMA toxicity 1 
GBL & MDMA toxicity 1 
GHB, MDMA, MDA, alcohol, diazepam & diltiazem toxicity  1 
Combined drug and alcohol poisoning                                                                1 
Inhalation of products of combustion 1 
Drowning, intoxication with MDMA and ecstasy                                                  1 
Pulmonary thromboembolism, suspected chronic drug use                                1 
Unascertained 1 
Not available 2 
 
 
Summary 
Since the first known death in the UK associated with the ingestion of GHB/GBL 
in 1995, there have been at least 47 cases in which these substances were 
implicated. Of these 4 involved GBL, mostly in 2005-6, including one case on its 
own. The number of cases appears to have first peaked in 2001-2 and rising to 
higher levels in 2005-6. 
  
Only 7/47 involved GHB/GBL on its/their own. The majority of cases involved the 
ingestion of at least two other substances, typically alcohol and/or stimulants. 
There was considerable variability in the range of GHB/GBL levels at post 
mortem. In many instances the effects on respiratory depression of GHB/GBL 
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were enhanced by the presence of alcohol and other CNS depressants such as 
benzodiazepines and opiates/opioids 
 
Where the circumstances were known, the majority (232/41) of deaths followed 
recreational use, often by individuals with a history of substance use (63% of all 
deaths where addict status was known). A small number of cases involved the 
use of GHB to aid sleep and in one of these to assist body-building. 
 
Most cases were male (72%), White (93%) where ethnicity was known, and aged 
less than 35 years of age (80%), and occurred in Metropolitan areas (74%), and 
were accidental in nature (80% where the circumstances are known).  
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